| Jul 17 |
4D Molecular Therapeutics, Inc. (FDMT) Special Call Transcript
|
| Jul 17 |
4D Molecular Therapeutics falls 30% following phase 2 wet AMD candidate data
|
| Jul 17 |
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
|
| Jul 12 |
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
|
| Jul 8 |
4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock?
|
| Jun 24 |
4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment
|
| Jun 24 |
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
|
| Jun 18 |
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
|
| Jun 8 |
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
|
| Jun 6 |
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
|
